The FDA has approved a new genetics-based cancer treatment that could open the door for more targeted mesothelioma therapy.
The drug is called larotrectinib. The drug company Bayer sells it under the brand name Vitrakvi.
Larotrectinib is unique because it is not specific to any one type of cancer. Instead, larotrectinib is based on a patient’s genetic biomarkers. It is the first drug of its kind to gain approval by the FDA.
What is a Genetics-Based Cancer Treatment?
A genetics-based cancer treatment is a drug that targets certain genetic mutations. Doctors find these mutations by testing for biomarkers. One mutation could cause breast cancer, colon cancer, or even pleural mesothelioma.
Some kinds of mutations are connected to only one type of cancer. Other mutations cause a range of different types of cancer.
Larotrectinib is based on a genetic mutation called TRK gene fusion. TRK fusion can be the reason for several different cancers, including mesothelioma.
The new genetics-based cancer treatment blocks three kinds of TRK. No matter where the cancer occurs in the body, if TRK fusion is the cause, larotrectinib may help.
Vitrakvi for TRK Fusion Cancers
In clinical trials, 75 percent of patients with TRK fusion cancers responded to the treatment. Seventy-three percent of responses lasted for at least six months. The authors of the new report call this response rate “remarkable”.
Twenty-two percent of patients with TRK fusion cancers had a complete response. This means that the targeted mesothelioma therapy stopped their cancer in its tracks.
“We now have the first therapy approved for this genomic alteration, regardless of cancer type” says David Hyman, MD, chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center. Dr. Hyman was a principal investigator on the larotrectinib clinical trial.
Genetics-Based Cancer Treatment for Mesothelioma
The news about Vitrakvi is exciting for malignant mesothelioma patients. Mesothelioma is an aggressive cancer for which there are few good treatments.
This summer, researchers in Australia discovered that a small number of mesothelioma cases may be caused by TRK fusion. It was the first study to show a relationship between mesothelioma and TRK fusion. The study appeared in The Journal of Clinical Oncology.
In the study, most of the patients with this genetic abnormality had the biphasic mesothelioma subtype. Most also reported exposure to asbestos. For these mesothelioma patients, larotrectinib may offer a new treatment option.
Larotrectinib is also important because it shows how genetics-based cancer treatment is growing. The drug’s approval could pave the way for other kinds of targeted mesothelioma therapy.
One drawback of larotrectinib is that a cancer patient must have expensive genetic testing to find out if it could work for them. Immunohistochemical testing (IHC) can cost thousands of dollars.
Before the FDA approved larotrectinib, it was granted Orphan Drug status. An orphan drug is a drug designed to treat people with very rare cancers like mesothelioma.
About 2,500 American receive a mesothelioma diagnosis every year.
Sources:
Laetsch, TW, and Hawkins, DS, “Larotrectinib for the treatment of TRK fusion solid tumors”, October 24, 2018, Expert Review of Anticancer Therapy, https://www.tandfonline.com/doi/abs/10.1080/14737140.2019.1538796?journalCode=iery20
Peters, G, et al, “NTRK and ALK rearrangements in mesothelioma and lung carcinoid”, June 2018, Journal of Clinical Oncology, http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e20558
Drilon, A, et al, “Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children”, August 22, 2018, New England Journal of Medicine, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857389/
The post Genetics-Based Cancer Treatment Could Mean New Hope for Mesothelioma appeared first on Surviving Mesothelioma.
from Surviving Mesothelioma https://ift.tt/2TSXXPs
via IFTTT
Most prostate cancers are adenocarcinomas, cancers that arise in glandular cells of the prostate’s epithelial tissue. Prostate cancers usually progress slowly and produce no symptoms in the initial stages. Eventually, the tumor may enlarge like mine use too, the prostate gland, pressing on the urethra and causing painful or frequent urination and blood in the urine. So I was so uncomfortable with this prostate cancer diseases then I decided to do online search on how to cure cancer because I well have read a lot about herbal medicine, I came across a lot of testimony how Dr Itua cure HIV/herpes then Cancer was listed below the comment.with courage I contacted Dr Itua and he sent me his herbal medicine through Courier service then I was asked to pick it up at my post office which i quickly did. I contacted Dr Itua that i have received my herbal medicine so he instructs me on how to drink it for three weeks and that is how Dr Itua Herbal Medicine cure my prostate Cancer, The treatment takes three weeks and I was cured completely. Dr Itua is a god sent and I thank him every day of my life. Contact him now On:Email:drituaherbalcenter@gmail.com/ Whatsapp:+2348149277967.
ReplyDeleteHe listed to that he can as well cure the following diseases below.... Cerebral Amides. Lung Cancer,Brain cancer,Esophageal cancer,Gallbladder cancer,Gestational trophoblastic disease,Head and neck cancer,Hodgkin lymphoma Intestinal cancer,Kidney cancer,Leukemia,Liver cancer,Melanoma,Mesothelioma,Multiple myeloma,Neuroendocrine tumors,Hodgkin lymphoma,Oral cancer,Ovarian cancer,Sinus cancer,Soft tissue sarcoma,Spinal cancer,Stomach cancer,Testicular cancer,Throat cancer,Thyroid Cancer,Uterine cancer,Vaginal cancer,Vulvar cancer. Alzheimer's disease,Autism,measles, tetanus, whooping cough, tuberculosis, polio and diphtheria Adrenocortical carcinoma. Alma, Uterine Cancer, Breast Cancer, Allergic diseases. Kidney cancer, Love Spell, Glaucoma., Cataracts,Macular degeneration,Cardiovascular disease,Lung disease.Enlarged prostate,Osteoporosis.Generalized dermatitis,Alzheimer's disease,Brain Tumor,Lupus,Endomertil Cancer, cerebrovascular diseases
Dementia.Colo rectal cancer, Lottery Spell, Bladder Cancer, Skin Cancer,Ovarian Cancer,Pancreatic Cancer, HIV /Aids,Brain Tumor, Herpes, Non-Hodgkin lymphoma, Inflammatory bowel disease, Copd, Diabetes, Hepatitis